STOCK TITAN

Curis (CRIS) S-3 Filings

CRIS NASDAQ

Here are the S-3 shelf registrations from Curis Inc (CRIS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.

Rhea-AI Summary

Curis, Inc. (CRIS) registered up to 33,333,360 common shares for resale by selling stockholders: 2,574,517 shares of common stock, 14,092,163 shares underlying October 2026 pre-funded warrants and 16,666,680 shares underlying October 2026 common warrants. The registration statement must become effective before sales; warrant shares may be offered only after exercise. Curis receives no proceeds from resales, but may receive cash proceeds from warrant exercises.

The pre-funded warrants are immediately exercisable at $0.01 per share. Common warrants are exercisable beginning April 19, 2027 at $0.60 per share and expire April 19, 2032. Beneficial-ownership limits are 4.99% or 9.99%, as applicable, and may be increased on 61 days’ notice but cannot exceed 19.99%. Curis’ 2025 audited financial statements include an explanatory paragraph concerning its ability to continue as a going concern.

Rhea-AI Summary

Curis, Inc. is registering 107,706,700 shares of common stock for resale by investors who participated in a January 2026 private financing. These shares come from Series B preferred stock and Series A, B and C warrants (or related pre-funded warrants) that can convert into common stock.

The company will not receive proceeds from investors’ resale of these shares, though it will receive cash if warrants are exercised. Curis is a biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor being studied in lymphoma and chronic lymphocytic leukemia. Its stock trades on Nasdaq under the symbol CRIS.